Kazia Therapeutics Limited
ASX:KZA.AX
0.08 (AUD) • At close November 13, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Kazia Therapeutics Limited |
Symbool | KZA.AX |
Munteenheid | AUD |
Prijs | 0.08 |
Beurswaarde | 18,907,919 |
Dividendpercentage | 0% |
52-weken bereik | 0.051 - 0.24 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. John E. Friend II, M.D. |
Website | https://www.kaziatherapeutics.com |
An error occurred while fetching data.
Over Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)